CARLSBAD, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) ( AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the second quarter of 2023.
Recent Highlights:
- Second quarter revenue of $5.3 million grew 30% year-over-year, reflecting strong procedure volume growth and improved capital sales
- Quarterly AcQMap procedure volumes set a new record and increased 21% compared to the second quarter of 2022
- Received FDA 510K clearance for AcQMap 9 next generation software platform featuring advanced algorithms and automation to improve diagnostic capabilities and procedure workflow
- Significant improvements in non-GAAP gross margin and cash burn resulting from disciplined focus on operational excellence
“Our second quarter performance reflects significant progress on our key strategic initiatives to return our business to growth while driving further operational improvement. During the second quarter of 2023, we achieved record procedure volumes, as focused commercial execution, pull through from the AcQMap 8.5 software launch, and the positive results from the RECOVER AF study supported accelerated AcQMap adoption,” said David Roman, President & CEO of Acutus Medical. “The strategic actions we have successfully undertaken over the past year, along with our team’s crisp execution, are driving momentum in our business and enabling our mission to create a new paradigm for the diagnosis and treatment of complex cardiac arrhythmias.”
Second Quarter 2023 Financial Results
Revenue was $5.3 million for the second quarter of 2023, an increase of 30% compared to $4.1 million for the second quarter of 2022. The improvement over the same quarter last year was primarily driven by disposables sales, higher capital conversions, increases in service, rent and other revenue, and sales through the Company’s distribution agreement with Medtronic.
Non-GAAP gross margin was negative 49% for the second quarter of 2023 compared to negative 129% for the same quarter last year. The improvement was driven by higher production volumes, improved product and geographic mix, lower manufacturing variances, and a reduced manufacturing overhead structure.
Non-GAAP operating expenses were $14.5 million for the second quarter of 2023 compared with $19.7 million in the same quarter last year. The decrease in operating expenses resulted from the Company’s restructuring actions in the first half of 2022, reduced discretionary spend, and the reprioritization of certain research and development programs.
Non-GAAP net loss for the second quarter of 2023 was $17.6 million, or $0.60 per share on a weighted average basic and diluted outstanding share count of 29.0 million, compared to non-GAAP net loss of $26.2 million, or $0.93 per share on a weighted average basic and diluted outstanding share count of 28.3 million, for the second quarter of 2022.
Cash, cash equivalents, marketable securities and restricted cash were $61.5 million as of June 30, 2023.
2023 Outlook
The company now expects full year 2023 revenue to be in a range from $20.0-$22.0 million.
Non-GAAP Financial Measures
This press release includes references to non-GAAP net loss and non-GAAP basic and diluted net loss per share, which are non-GAAP financial measures, to provide information that may assist investors in understanding the Company’s financial results and assessing its prospects for future performance. The Company believes these non-GAAP financial measures are important indicators of its operating performance because they exclude items that are primarily non-cash accounting line items unrelated to, and may not be indicative of, the Company’s core operating results. These non-GAAP financial measures, as Acutus calculates them, may not necessarily be comparable to similarly titled measures of other companies and may not be appropriate measures for comparing the performance of other companies relative to the Company. These non-GAAP financial results are not intended to represent and should not be considered to be more meaningful measures than, or alternatives to, measures of operating performance as determined in accordance with GAAP. Non-GAAP net loss is defined as net loss before income taxes, adjusted for stock-based compensation, amortization of acquisition-related intangibles, employee retention credit, goodwill impairment, restructuring charges, changes in the fair value of contingent consideration, gain on sale of business, loss on debt extinguishment and change in fair value of warrant liability and other adjustments. To the extent such non-GAAP financial measures are used in the future, the Company expects to calculate them using a consistent method from period to period. A reconciliation of the most directly comparable GAAP financial measure to the non-GAAP financial measure has been provided under the heading “Reconciliation of GAAP Results to Non-GAAP Results” in the financial statement tables attached to this press release.
Webcast and Conference Call Information
Acutus will host a conference call to discuss the second quarter 2023 financial results after market close on Monday, August 7, 2023 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To access the live call via telephone, please register in advance using the link: https://register.vevent.com/register/BI93bb82b6296f43ae9eb227af3e9a6f7f. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique personal PIN that can be used to join the call. The live webinar of the call may be accessed at https://ir.acutusmedical.com.
About Acutus
Acutus is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. Acutus is committed to advancing the field of electrophysiology with a unique array of products and technologies which will enable more physicians to treat more patients more efficiently and effectively. Through internal product development, acquisitions and global partnerships, Acutus has established a global sales presence delivering a broad portfolio of highly differentiated electrophysiology products that provide its customers with a complete solution for catheter-based treatment of cardiac arrhythmias. Founded in 2011, Acutus is based in Carlsbad, California.
Caution Regarding Forward-Looking Statements
This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to continue to manage expenses and cash burn rate at sustainable levels, continued acceptance of its products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase the Company’s systems and the timing of such purchases, competitive factors, changes resulting from healthcare policy in the United States and globally including changes in government reimbursement of procedures, dependence upon third-party vendors and distributors, timing of regulatory approvals, the impact of the coronavirus (COVID-19) pandemic and Acutus’ response to it and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, Acutus undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
| Investor Contact: | Media Contact: |
| Caroline Corner | Rhiannon Pickus |
| Westwicke ICR | Acutus Medical, Inc. |
| D: 415-202-5678 | M: 442-232-6094 |
| [email protected] | [email protected] |
| ACUTUS MEDICAL, INC. Condensed Consolidated Balance Sheets (in thousands, except per share amounts) | |||||||
| June 30, 2023 | December 31, 2022 | ||||||
| (unaudited) | |||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 23,055 | $ | 25,584 | |||
| Marketable securities, short-term | 31,461 | 44,863 | |||||
| Restricted cash, short-term | 7,002 | 5,764 | |||||
| Accounts receivable | 7,670 | 21,085 | |||||
| Inventory | 15,671 | 13,327 | |||||
| Employer retention credit receivable | — | 4,703 | |||||
| Prepaid expenses and other current assets | 2,444 | 2,541 | |||||
| Total current assets | 87,303 | 117,867 | |||||
| Property and equipment, net | 7,245 | 9,221 | |||||
| Right-of-use asset, net | 3,533 | 3,872 | |||||
| Intangible assets, net | 1,483 | 1,583 | |||||
| Other assets | 731 | 897 | |||||
| Total assets | $ | 100,295 | $ | 133,440 | |||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 5,492 | $ | 4,721 | |||
| Accrued liabilities | 9,759 | 9,686 | |||||
| Contingent consideration, short-term | — | 1,800 | |||||
| Operating lease liabilities, short-term | 466 | 319 | |||||
| Warrant liability | 2,504 | 3,346 | |||||
| Total current liabilities | 18,221 | 19,872 | |||||
| Operating lease liabilities, long-term | 3,679 | 4,103 | |||||
| Long-term debt | 34,634 | 34,434 | |||||
| Other long-term liabilities | 20 | 12 | |||||
| Total liabilities | 56,554 | 58,421 | |||||
| Commitments and contingencies | |||||||
| Stockholders' equity | |||||||
| Preferred stock, $0.001 par value; 5,000,000 shares authorized as of June 30, 2023 and December 31, 2022; 6,666 shares of the preferred stock, designated as Series A Common Equivalent Preferred Stock, are issued and outstanding as of June 30, 2023 and December 31, 2022 | — | — | |||||
| Common stock, $0.001 par value; 260,000,000 shares authorized as of June 30, 2023 and December 31, 2022; 29,206,570 and 28,554,656 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively | 29 | 29 | |||||
| Additional paid-in capital | 597,578 | 594,173 | |||||
| Accumulated deficit | (552,975 | ) | (518,314 | ) | |||
| Accumulated other comprehensive loss | (891 | ) | (869 | ) | |||
| Total stockholders' equity | 43,741 | 75,019 | |||||
| Total liabilities and stockholders' equity | $ | 100,295 | $ | 133,440 | |||
| ACUTUS MEDICAL, INC. Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (in thousands, except per share amounts) | |||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| (unaudited) | |||||||||||||||
| Revenue | $ | 5,289 | $ | 4,076 | $ | 9,458 | $ | 7,757 | |||||||
| Cost of products sold | 8,063 | 9,697 | 14,852 | 16,638 | |||||||||||
| Gross profit | (2,774 | ) | (5,621 | ) | (5,394 | ) | (8,881 | ) | |||||||
| Operating expenses (income): | |||||||||||||||
| Research and development | 6,799 | 7,935 | 12,916 | 15,938 | |||||||||||
| Selling, general and administrative | 9,284 | 14,143 | 18,849 | 28,528 | |||||||||||
| Goodwill impairment | — | — | — | 12,026 | |||||||||||
| Restructuring | 463 | — | 475 | 949 | |||||||||||
| Change in fair value of contingent consideration | (77 | ) | 948 | 123 | 955 | ||||||||||
| Gain on sale of business | (2,072 | ) | (43,575 | ) | (3,279 | ) | (43,575 | ) | |||||||
| Total operating expenses (income) | 14,397 | (20,549 | ) | 29,084 | 14,821 | ||||||||||
| Income (loss) from operations | (17,171 | ) | 14,928 | (34,478 | ) | (23,702 | ) | ||||||||
| Other income (expense): | |||||||||||||||
| Loss on debt extinguishment | — | (7,947 | ) | — | (7,947 | ) | |||||||||
| Change in fair value of warrant liability | (604 | ) | — | 842 | — | ||||||||||
| Interest income | 824 | 27 | 1,676 | 51 | |||||||||||
| Interest expense | (1,395 | ) | (1,290 | ) | (2,701 | ) | (2,701 | ) | |||||||
| Total other expense, net | (1,175 | ) | (9,210 | ) | (183 | ) | (10,597 | ) | |||||||
| (Loss) income before income taxes | (18,346 | ) | 5,718 | (34,661 | ) | (34,299 | ) | ||||||||
| Income tax benefit | — | ||||||||||||||
